

はじめに

Adenylate Kinase (AK) (EC 2.7.4.3, hAK1)

(1) アデニル酸キナーゼ (AK) は、細胞質内に普遍的に存在する酵素で、 Mg^{2+} の存在下で以下の可逆的反応を触媒する。



(2)AK は、2つのヌクレオチド基質結合部位が存在する。一つは、MgATP あるいは MgADP 部位、もう一つは AMP または ADP 部位である。この酵素は、Mg²⁺の金属イオンの存在下、リン酸転移反応を可逆的に触媒する。

(3) ヒト AK(hAK1) は、194 のアミノ酸から構成される分子量 21,400 の球状蛋白質で、細菌から、哺乳動物まで広く存在し、3つのアイソザイムが存在する。AK1 は細胞質に存在し、骨格筋、脳、赤血球にみられる。AK2 は、ミトコンドリア内膜に、AK3 は、ミトコンドリアマトリックスに存在し、肝臓、腎臓にみられる。

(4) 3 Å X線回折を用いたブタ骨格筋 AK の構造解析により、10 の a ヘリックスと 5 つの b-鎖構造を有する (Schulz et al., 1974)。

(5) ヌクレオチド結合タンパク質 (ras, p21, c-has/bas protein, the b-subunit of F₁-ATPase, G-protein) と AK において、アミノ酸一次構造の相同性の高い領域が存在し、ATP 結合蛋白 のモデルとして応用研究されている。

(6) 部位特異的変異導入による標的アミノ酸残基の変異体の作製

は、hAK1 では、R44, R97, R132, R138, R149, D119 残基において、ニワトリ AK では、P17, K21, C25, H36, T39, R44, D93,

R97, R128, R132, R138, R149, L190、大腸菌 AK では、P9, G10, K13, Q28, F86, P87, R88, L107, Y133 に関して行われ、AK の X線回折や NMR を用いた構造機能解析研究に用いられている。

(7)X 線回折により想定された AK 立体構造モデルで AMP 結合部位が想定された。hAK1 の Arg 残基 (R44, R132, R138) は、酵素活性に不可欠な残基であると示唆された。(Kim et al, 1990).

本研究の目的

a) hAK1 の酵素活性に最低必要と思われる重要なアミノ酸残基を決定していくために、N 末端と C 末端のリジン残基 (Lys9, Lys21, Lys27, Lys31, Lys194) に対して部位特異的変異導入を行う。

b) 野生型 AK と変異型 AK の生理学的属性を定常状態でのキネテックス解析により比較し、リジン残基側鎖に存在する陽性荷電の ϵ -アミノ基の欠如が酵素活性に与える影響を考察する。

Introduction

Adenylate Kinase (AK) (EC 2.7.4.3, hAK₁)

1. AK is a ubiquitous enzyme catalyzing the following reversible reaction in the presence of Mg²⁺:






2. There are two distinct nucleotide-binding sites in AK, one for metal-chelated ATP or ADP, and the other for unchelated AMP or ADP.

3. The AK family consists of three isoenzymes: AK₁, AK₂, and AK₃. AK₁ is localized in mammalian cytosol, AK₂ in mitochondria intermembrane space, and AK₃ in mammalian mitochondria matrix.
4. The molecular weight of human AK₁ (hAK₁) is 21.7 kDa known to be one of the smallest phosphotransferases. AK has ten α -helices and five β -strands (Schulz et al., 1974).
5. AK is often cited as an example of a typical ATP binding protein when structural topological comparisons or amino acid homology comparisons are made of the nucleotide-binding proteins such as ras, p21, c-ha/bas protein, the β -subunit of F₁-ATPase, and G-protein.

7. Site-directed mutagenesis was carried out in hAK1 (R44, R97, R132, and R138), chicken AK (P17, K21, C25, H36, T39, R44, D93, R97, R128, R132, R138, R149, and L190), and *E. coli* AK (P9, G10, K13, Q28, F86, P87, R88, L107, and Y133).
8. The ATP site in the original X-ray model was reassigned to the AMP site; arginine residues in hAK1 were determined to be essential for catalytic activity (Kim et al, 1990).

In this study, to elucidate the minimum requirement of amino acid residues at the active center in hAK1 and to clarify the physiological properties of normal and abnormal AK enzymes, we substituted key lysine residues in the N- and C-terminal domains of the proposed

X-ray model (Kim et al., 1990). To elucidate the function of the positive e-amino groups of the lysine residues, we mutated Lys9, Lys21, Lys27, and Lys31 in the head domain, and Lys194 in the tail domain of hAK1. These mutants were analyzed by steady-state kinetics.



Materials and Methods

A) Materials.

1. The plasmid pMEX8-hAK1 (Ayabe et al., 1996, *Biochem. Mol. Biol. Int.* 38, 373-381.) was used for site-directed random mutagenesis with a Sculptor™ in vitro Mutagenesis Kit (Amersham).

B) Purification of single strand pMEX8-hAK1 DNA.

1. A single colony of TG1/pMEX8-hAK1 was cultured in 10 ml of a TYP medium containing 50 mg/ml of ampicillin overnight until the A_{600} was approximately 0.5. Helper phage (VCS-M13, Stratagene) was added to the culture medium at a multiplicity of infection of between 10 and 20 (a phage : cell ratio of between 10 : 1 and 20 : 1) with 25 mg/ml of kanamycin.

2. The single strand template DNA was precipitated with a solution of polyethylene glycol 6000 and 2.5M NaCl and extracted by phenol and chloroform.

C) Random site-directed mutagenesis of hAK1.

1. The antisense primers were 5'-CGAAGATGATYXXAGTCTTCTTAAGC-3' for Lys9 residue, 5'-GCACTGGGTACCYXXGCCAGAACC-3' for Lys21, 5'-GCA CGATYXXCTCGCACTGGG -3' for Lys27, 5'GTGTAGCCGTAYXXCTGCAC GATTTTC-3' for Lys31, 5'-CCAGCTGACCYXXTTCCATGATTTTC-3' for Lys63, 5'-GTTTCGCCGCGYXXCAGCAGGCG-3' for Lys131, and 5'-CGAAGATGAT YXXAGTCTTCTTAAGC-3' for Lys194. The underlined three letters, YXX in the primer, represent a codon for each target residue (Y=G or C; X=A, G, C, or T). The phosphorylation of the primers was performed with T₄ Polynucleotide Kinase.
2. Random site-directed mutagenesis was carried out using the Sculptor™ *in vitro* Mutagenesis Kit and a homoduplex mutant pMEX8-hAK1 DNA was constructed with the method based on the phosphorothioate technique.

D) Purification of mutant double strand pMEX8-hAK1 plasmid.

1. The competent cells of TG1 were transformed with the above homoduplex mutant DNA, which were cultured on an LB plate containing 50 mg/ml of ampicillin. Each grown clone was transferred into 10 ml of the LB medium containing 50

mg/ml of ampicillin and purified according to the directions of the Flex Prep Purification Kit (Pharmacia).

E) Screening of mutant plasmid by DNA sequence.

1. Mutant double strand plasmid was screened by Sanger's dideoxy method with polymerase chain reaction (PCR).
2. AmpliTaq™ DNA Polymerase solution and Taq DNA Polymerase were mixed in a 9:1 ratio as a cycling mixture. Eight ml of a master mixture consisted of 2.8 mg of double strand DNA, 2 pmol of the FITC-labeled sequence-primer, 1 ml of DMSO, which was incubated at 95°C for 10 min, and immediately cooled on ice.
3. Two ml of the cycling mixture and 0.2 unit of the Perfect Match Enhancer (Stratagene) were mixed into the cooled master mixture.
4. PCR conditions were initial denaturation at 95°C for 5 min, 20 cycles of 95°C for 30 s, 53°C for 30 s, 72°C for 60 s, 20 cycles of 95°C for 30 s and 72°C for 60 s. PCR products were denatured by 95% formamide. The DNA sequences of both ends of the mutant plasmid were reconfirmed to avoid undesirable mutations in any other regions of the hAK1 gene.

F) Expression and purification of wild-type AK (WTAK) and mutant enzymes.

1. TG1/pMEX8-hAK1 (WTAK) and TG1/mutant-pMEX8-hAK1 were cultured in 10 ml of LB medium containing 50 mg/ml of ampicillin at 37°C for 12 h; these were transferred into 250 ml of LB medium with ampicillin. The culture medium was incubated for 1 h at 37°C, and isopropyl-b-D-thio-galactopyranoside (IPTG) was added at a final concentration of 1 mM and continued to culture for 16 h.
2. The harvested E. coli cells were resuspended in 10 ml of standard buffer [1 mM EDTA, 0.1 mM dithiothreitol (DTT), 20 mM Tris-HCl, pH 7.4], which was disrupted by sonication at 20 kHz, 20 W for 3 min at 4°C using a sonicator. The cell debris was removed by centrifugation at 12,000 x g for 20 min.
3. The supernatant (10 ml) was loaded onto a Blue Sepharose CL-6B affinity column (ϕ 1 X 5 cm), which had been pre-equilibrated with the standard buffer, and eluted by a NaCl gradient (0 to 1 M NaCl) at a velocity of 0.5 ml/min at 4°C. Each fraction was examined by a 12.5% polyacrylamide gel electrophoresis in the presence of 1% sodium dodecylsulfate (SDS-PAGE) to confirm the presence of an AK protein of 21.7 kDa. The AK fraction was concentrated by centrifuging with Centriplus-10 (Amicon).

4. The AK solution (1 ml) was then loaded onto a Superose 12 column (ϕ 1 x 30 cm) which had been equilibrated with an imidazole buffer (5 mM imidazole-HCl, 1 mM EDTA, 0.1 mM DTT, pH 6.9) and eluted at a velocity of 0.5 ml/min at 40°C. Each fraction was also examined by a 12.5% SDS-PAGE to confirm the presence of a single AK solution as determined by the method of Lowry et al.

G) Steady-state kinetics of forward reaction of AK.

1. The forward reaction mixture in a total of 1 ml contained 75 mM triethanolamine hydrochloride (pH 7.4), 120 mM KCl, 0.2 mM NADH, 0.3 mM phosphoenolpyruvate, 0.3 mg/ml bovine serum albumin, 10 units of lactate dehydrogenase (LDH), 5 units of pyruvate kinase (PK), and 1.0 mM MgSO₄, and the various concentrations of MgATP₂₋ and AMP₂₋ were as follows: five combinations selected from 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 5.0 mM MgATP₂₋ and at a fixed concentration of 2 mM AMP₂₋ were used in the determination of the apparent Michaelis constant (K_m) for MgATP₂₋. Five combinations selected from 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 5.0 mM AMP₂₋ and a fixed concentration of 2 mM MgATP₂₋ were used in the determination of the apparent K_m for AMP₂₋.
2. The reaction was initiated by addition of 10 μ l of the recombinant hAK1 solution

diluted to desired concentrations. The initial velocity of the forward reaction was measured by observing the absorbance change at 340 nm with a Cary 2290 spectrophotometer [for NADH, in a coupled-enzyme assay in the presence of PK and LDH to monitor the ADP formation at 25 °C as previously described].

3. K_m and V_{max} were estimated using a double-reciprocal plot, and k_{cat} was calculated by dividing V_{max} by the total amount of enzyme (Et) present in the reaction mixture. One unit of enzyme activity is defined as the amount of enzyme that produces 1 mmol of ADP per minute.

Experimental Procedures

1. Culture of TG1/pMEX8-hAK1 (TG1 transformed with pMEX8-hAK1) in LB medium.
2. Addition of helper phage (VCS-M13) at a multiplicity of infection of between 10 and 20.
3. Purification of single strand pMEX8-hAK1 DNA with a solution of polyethylene glycol 6000 and 2.5M NaCl and extraction with phenol and chloroform.
4. Annealing of antisense primers to the single strand pMEX8-hAK1 DNA.
5'-CGAAGATGATYXXAGTCTTCTTAAGC-3' for Lys9,
5'-GCACTGGGTACCYXXGCCAGAACC-3' for Lys21,
5'-GCACGATYXXCTCGCACTGGG -3' for Lys27,
5'-GTGTAGCCGTAYXXCTGCACGATTTTC-3' for Lys31,

5'-CCAGCTGACCYXXTTCCATGATTTC-3' for Lys63,

5'-GTTTCGCCGCGYXXCAGCAGGCG-3' for Lys131,

5'-CGAAGATGATYXXAGTCTTCTTAAGC-3' for Lys194.

YXX represents a codon for each target residue (Y=G or C; X=A, G, C, or T)

5. Construction of a homoduplex mutant pMEX8-hAK1 DNA by site-directed mutagenesis with the method based on the phosphorothioate technique.
6. Transformation of the homoduplex mutant pMEX8-hAK1 with competent TG1 cells.
7. Culture of TG1 transformed with the mutant homoduplex DNA.
8. Purification of double strand pMEX8-hAK1 DNA.
9. Screening of mutant pMEX8-hAK1 by DNA sequence with PCR.
10. Culture and expression of the confirmed mutant pMEX8-hAK1 plasmid in LB

medium.


12. Sonication of the harvested *E. coli*.
13. Purification with a Blue Sepharose CL-6B chromatography and elution by a NaCl gradient (0 to 1 M NaCl).
14. Confirmation of the presence of an AK protein of 21.7 kDa with 12.5% SDS- PAGE.
15. Concentration of the AK fraction by centrifuging with Centriplus-10 (Amicon).
16. Purification of AK sample with Superose 12 chromatography.
17. Confirmation of the presence of an AK protein with 12.5% SDS-PAGE.
18. Measurement of the concentration of AK protein.
19. Assay of wild type AK and the recombinant mutant AK.

Steady-state kinetics of forward reaction of AK.

Five combinations selected from 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 5.0 mM MgATP²⁻ and at a fixed concentration of 2 mM AMP²⁻ were used in the determination of the apparent Michaelis constant (K_m) for MgATP²⁻.

Five combinations selected from 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0, 5.0 mM AMP²⁻ and a fixed concentration of 2 mM MgATP²⁻ were used in the determination of the apparent K_m for AMP²⁻.

K_m and V_{max} were estimated using a double-reciprocal plot, and k_{cat} was calculated by dividing V_{max} by the total amount of enzyme (E_t) present in the reaction mixture. One unit of enzyme activity is defined as the amount of enzyme that produces 1 μ mol of ADP per minute.



Forward Reaction

<Reaction Mixture (1ml) of the ADP formation reaction>

75 mM Triethanolamine HCl (pH 7.5)

120 mM KCl

0.2 mM NADH

0.3 mM Phosphoenolpyruvate

1 mM MgSO₄

1 mM ATP

1.2 mM AMP

0.3 mg/ml Bovine serum albumine (BSA)

15 U Lactate dehydrogenase

6 U Pyruvate kinase

AK sample

AK, Mg²⁺

↓



Pyruvate Kinase (PK)



Lactate Dehydrogenase (LDH)



↑

observe reduction of NADH at 340 nm

Reverse Reaction

<Reaction mixture (1ml) of the ATP formation reaction>

50 mM Tris HCl (pH 7.4)

100 mM KCl

2 mM MgCl₂

7 mM D-glucose

2 mM ADP

0.6 mM NADP

0.1 mM EDTA

0.5 mg/ml Bovine serum albumine (BSA)

10 U Hexokinase

5 U Glucose-6-phosphate dehydrogenase

AK sample

AK, Mg²⁺

↓



Hexokinase (HK)



G-6-P Dehydrogenase



(6-phosphoglucono-d-lactone) ↑


observe increase of NADPH at 340 nm

Forward Reaction

AK, Mg²⁺
↓



Pyruvate Kinase (PK)



Lactate Dehydrogenase (LDH)



observe reduction at 340 nm

Reaction Mixture (1ml) of the ADP formation reaction

75	mM	Triethanolamine HCl (pH 7.5)
120	mM	KCl
0.2	mM	NADH
0.3	mM	Phosphoenolpyruvate
1	mM	MgSO ₄
1	mM	ATP
1.2	mM	AMP
0.3	mg/ml	Bovine serum albumine (BSA)
15	U	Lactate dehydrogenase
6	U	Pyruvate kinase
		AK sample

Reverse Reaction

AK, Mg²⁺



Hexokinase (HK)



G-6-P Dehydrogenase



6-phosphoglucono- δ -lactone

observe increase at 340 nm

Reaction mixture (1ml) of the ATP formation reaction

50	mM	Tris HCl (pH 7.4)
100	mM	KCl
2	mM	MgCl ₂
7	mM	D-glucose
2	mM	ADP
0.6	mM	NADP
0.1	mM	EDTA
0.5	mg/ml	Bovine serum albumine (BSA)
10	U	Hexokinase
5	U	Glucose-6-phosphate dehydrogenase
		AK sample

One unit of activity = 1 μ mol ATP/min at pH8.0 and 30 oC.

$$\Delta \text{O.D./min} \times 0.1607 = \frac{\text{units/cuvette}}{(10 \mu\text{l})} \times \text{dilution factor} \quad (\times 100)$$

Extinction coefficient for reduced NADP₊ = 6.22 X 10⁶ cm²/mole.

$$\text{O.D.} = E * c * b$$

E=Extinction coefficient

c= concentration (in moles/liter)

b=light path (in cm)

$$\begin{aligned} \text{O. D.} &= 6.22 \times 10^6 \text{ cm}^2 / \text{mmol} * (c) * (1 \text{ cm}) \\ &= 6.22 \times 10^6 \text{ cm}^3 / \text{mmole} * (c) \\ &= 6.22 \times 10^6 \text{ liters/mole} * (c). \end{aligned}$$

or

$$\text{O.D.} = 6.22 \times 10^3 \text{ ml/mole} \cdot (c)$$

$$c = (\text{O.D.} \cdot \text{mmoles} / 6.22 \times 10^3 \text{ ml}) \times 3 \text{ ml /cuvette}$$

$$= (\text{O.D.} \cdot \mu\text{mol/cuvette}) \times 3 \text{ ml} / 6.22 \text{ ml}$$

$$= \text{O.D.} \cdot \mu\text{moles/cuvette} \times 0.1607$$

$$\Delta \text{ O.D./min} \times 0.1607 \mu\text{moles/cuvette}$$

$$= \text{units/cuvette} \times \text{dilution factor/aliquote}$$

$$= \text{units/ml}$$

$$\text{Activity (U/ml)} = \Delta \text{ O. D. /min} \times 0.1607 \text{ mmoles/cuvette} \cdot \text{dilution factor/aliquote}$$

! " # " \$ " %

One unit of activity = 1 μ mol ATP/min at pH7.4 and 25 $^{\circ}$ C.

$$\Delta \text{O.D./min} \times 0.1607 = \text{units/cuvette} / \text{aliquot} \times \text{dilution factor}$$
$$(1/6.22 \times 10^6 \text{ cm}^2/\text{mole}) \quad (10 \mu\text{l}) \quad (\times 100)$$

Extinction coefficient for reduced NADH
= $6.22 \times 10^6 \text{ cm}^2/\text{mole}$.

E=Extinction coefficient
O.D. =E X c X b c= concentration (in moles/liter)
 b=light path (in cm)

or


$$\text{O.D.} = 6.22 \times 10^3 \text{ ml/mole} \times (c)$$
$$c = (\text{O.D.} \times \text{mmoles} / 6.22 \times 10^3 \text{ ml}) \times 3 \text{ ml /cuvette}$$
$$= (\text{O.D.} \times \mu\text{mol/cuvette}) \times 3 \text{ ml} / 6.22 \text{ ml}$$
$$= \text{O.D.} \times \mu\text{moles/cuvette} \times 0.1607$$

$$\Delta \text{O.D./min} \times 0.1607 \mu\text{moles/cuvette}$$
$$= \text{units/cuvette} \times \text{dilution factor/aliquote}$$
$$= \text{units/ml}$$

Activity (U/ml)

$$= \Delta \text{O. D. /min} \times 0.1607 \mu\text{moles/cuvette} \times \text{dilution factor/aliquote}$$

K194P (Lineweaver-Burk Plot)




$$1/V = 4.0557e-2 + 0.20189 \cdot 1/[S]$$

X ! " # \$ % & -1/Km
Y ! " # \$ % & 1/V

$$v = \frac{V[S]}{K_m + [S]}$$

$$K_m = \frac{k_{-1} + k_2}{k_{+1}}$$



$$\frac{d[ES]}{dt} = k_1 [E] [S] - (k_{-1} + k_2) [ES]$$

! " # \$ % & ' () * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < 4 1

$$v = \frac{d[P]}{dt} = k_2 [ES], [E]_0 = [E] + [ES], [S]_0 = [S] + [ES] + [P]$$

$$\Rightarrow [E]_0 \ll [S] \quad \& \quad [ES] \ll [S]_0$$

$$[P] \ll [S]_0$$

$$[S] \approx [S]_0 - [P]$$

$$\frac{d[ES]}{dt} = k_1 [S] ([E]_0 - [ES]) - (k_{-1} + k_2) [ES]$$


$$K_m = (k_{-1} + k_2) / k_1$$

$$[ES] = \frac{[E]_0 [S]}{K_m + [S]} (1 - \exp(-k_2 [S] t))$$

$$[S] \approx [S]_0 - [P]$$

$$v = \frac{d[P]}{dt} = k_2 \frac{[E]_0 [S]}{K_m + [S]} = \frac{V [S]}{K_m + [S]}$$

WTAK 2mM AMP fixed



WTAK 2mM ATP fixed




Table 2. Summary of kinetic parameters of wild-type hAK1 (WTAK) and mutant hAK1

Enzyme	$K_m(\text{MgATP}^{2-})$ (mM) (fold)	$K_m(\text{AMP}^{2-})$ (mM) (fold)	k_{cat} (s ⁻¹)	relative value (%)	$k_{cat}/K_m(\text{MgATP}^{2-})$ (%)	$k_{cat}/K_m(\text{AMP}^{2-})$ (%)
WTAK	0.27 (1.0) a	0.33 (1.0) a	571	(100.0) b	2.1×10^6 (100.0) b	1.7×10^6 (100.0) b
K194S	3.92 (14.5)	1.11 (3.4)	213	(37.3)	5.4×10^4 (2.6)	1.9×10^5 (11.2)
K194I	0.05 (0.2)	0.20 (0.6)	13.5	(2.4)	2.7×10^5 (12.9)	6.8×10^4 (4.0)
K194L	2.59 (9.6)	0.02 (0.1)	78	(13.7)	3.0×10^4 (1.4)	3.9×10^6 (229.4)
K194P	0.78 (2.9)	0.05 (0.2)	4.5	(0.8)	5.8×10^3 (0.3)	9.0×10^4 (5.3)
K194N	0.80 (3.0)	0.54 (1.6)	21	(3.7)	2.6×10^4 (1.2)	3.9×10^4 (2.3)
K194V	0.25 (0.9)	6.86 (20.8)	8	(1.4)	3.2×10^4 (1.5)	1.2×10^3 (7.1×10^{-2})

a Numbers in parentheses for K_m values indicate the relative change compared to the wild-type AK (the mutant/WTAK ratio).

b For calculation of k_{cat} value, molecular weight of 21,700 was employed and numbers in parentheses for k_{cat} and k_{cat}/K_m values represent % of WTAK.